<DOC>
	<DOCNO>NCT00963209</DOCNO>
	<brief_summary>RATIONALE : Estrogen promote growth endocrine sensitive breast cancer cell . Endocrine therapy tamoxifen citrate may fight breast cancer block use estrogen tumor cell . Pharmacokinetics -genomics impact efficacy treatment . PURPOSE : This phase III trial study blood sample see level active metabolite tamoxifen improved patient breast cancer .</brief_summary>
	<brief_title>Tamoxifen Citrate Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine increase tamoxifen citrate dose influence level major metabolite patient hormone-sensitive breast cancer . Secondary - To characterize population pharmacokinetic profile - To investigate role CYPs - To assess relation clinical symptom CYP2D6 genotype and/or active metabolite level - To explore correlation genotypes/metabolites level clinical outcome term tumor relapse . - To assess feasibility , efficacy , safety concentration-guided adjustment tamoxifen citrate dosage . - To conduct exploratory analysis base eventual new data come future . OUTLINE : Patients receive oral tamoxifen citrate ( dose 40 mg/day ) daily 4 month absence disease progression unacceptable toxicity . Blood sample collect PK , genotyping , phenotyping , analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Hormonesensitive breast cancer define &gt; 10 % estrogen receptor and/or &gt; 10 % progesterone receptor positivity immunohistochemistry Receiving treatment tamoxifen citrate must eligible exposure high dose PATIENT CHARACTERISTICS : No history deep venous thrombosis pulmonary embolism No history endometrial carcinoma No known history vaginal bleeding , endometriosis , endometrial hyperplasia , endometrial hypertrophy , and/or polyp Not pregnant nursing No contraindication tamoxifen citrate treatment No known allergy midazolam dextromethorphan PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>endocrine sensitive</keyword>
	<keyword>breast cancer</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>genotyping</keyword>
	<keyword>phenotyping</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Endoxifen</keyword>
</DOC>